Journal of Peking University(Health Sciences) ›› 2018, Vol. 50 ›› Issue (4): 640-644. doi: 10.3969/j.issn.1671-167X.2018.04.012

• Article • Previous Articles     Next Articles

Correlation between the new lung adenocarcinoma classification and epidermal growth factor receptor mutation

ZHANG Xiao-dong1, LIU De-ruo2△   

  1. (1.Department of Thoracic Surgery, Peking University International Hospital, Beijing 102206, China; 2.Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing 100029, China)
  • Online:2018-08-18 Published:2018-08-18
  • Contact: LIU De-ruo E-mail:deruoliu@sina.vip.com

Abstract: Objective: To evaluate the association of the histological subtype of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutation. Methods: A total of 94 patients with resected lung adenocarcinoma in the Department of Thoracic Surgery of China-Japan Friendship Hospital from Ja-nuary 2010 to December 2014 were enrolled in the study. All specimens were tested for EGFR mutation by a company. In the 94 patients, histological subtypes were classified according to the 2011 International Association for the Study of Lung Cancer and American Thoracic Society and European Respiratory Society classification. We compared the association with the histological subtype of lung adenocarcinoma with EGFR mutation frequency by the χ2 test, with SPSS 20.0. Results: The 94 patients of surgically resected lung adenocarcinomas were included in this analysis,of whom,47 were male and 47 female (male ∶female= 1 ∶1) . The median age was 61 (range: 24-79) years, and 48 of the 94 patients were 60 years and above. Regarding the pathological staging, 34 patients were diagnosed as Stage Ⅰ of the disease,17 as Stage Ⅱ,24 as Stage Ⅲ, and 19 as Stage Ⅳ. Among the 51 patients with EGFR mutation, exon 19 mutation was 22, exon 20 mutation was 2, exon 21 mutation was 26, exon 20 and 21 mutation were 1, and the total EGFR mutation rate was 54.3% (51/94). The cases of EGFR gene mutation of acinar predominant lung adenocarcinoma, lepidic predominant lung adenocarcinoma, papillary predominant lung adenocarcinoma, solid predominant lung adenocarcinoma, micropapillary predominant lung adenocarcinoma and mucious adenocarcinoma were 24, 14, 5, 5, 3, and 0, respectively. The rate of EGFR gene mutation of acinar predominant lung adenocarcinoma was higher than that of non-acinar predominant lung adenocarcinom, but there was not statistically significant (66.7% vs. 46.6%, P=0.057). The rate of EGFR gene mutation of solid predominant lung adenocarcinoma was lower than that of non-solid predominant lung adenocarcinom (26.3% vs. 61.3%, P=0.005). The rate of EGFR gene mutation of mucious adenocarcinoma was lower than that of non-mucious adenocarcinom (0 vs. 57.3%, P=0.018).Conclusion: There is heterogeneity of EGFR mutation in lung adenocarcinoma. The presence of lung adenocarcinoma with acinar indicates a higher EGFR mutation rate, while the solid and mucinous component indicates a lower EGFR mutation rate.

Key words: Epidermal growth factor receptor, Lung adenocarcinoma, Mutation

CLC Number: 

  • R655.3
[1] Yun-fei SHI,Hao-jie WANG,Wei-ping LIU,Lan MI,Meng-ping LONG,Yan-fei LIU,Yu-mei LAI,Li-xin ZHOU,Xin-ting DIAO,Xiang-hong LI. Analysis of clinicopathological and molecular abnormalities of angioimmunoblastic T-cell lymphoma [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 521-529.
[2] Xiao-juan ZHU,Hong ZHANG,Shuang ZHANG,Dong LI,Xin LI,Ling XU,Ting LI. Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 243-253.
[3] Yan XIONG,Bo ZHANG,Li-gong NIE,Shi-kai WU,Hu ZHAO,Dong LI,Ji-ting DI. Thoracic SMARCA4-deficient undifferentiated tumor-pathological diagnosis and combined immune checkpoint inhibitor treatment [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 351-356.
[4] Qiu-jun ZHOU,Pan GONG,Xian-ru JIAO,Zhi-xian YANG. Clinical and molecular genetic analysis of Angelman syndrome with oculocutaneous albinism type 2: A case report and literature review [J]. Journal of Peking University (Health Sciences), 2023, 55(1): 181-185.
[5] Yue WANG,Shuang ZHANG,Hong ZHANG,Li LIANG,Ling XU,Yuan-jia CHENG,Xue-ning DUAN,Yin-hua LIU,Ting LI. Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 853-862.
[6] Xiao-jing CHENG,Dong JIANG,Lian-hai ZHANG,Jiang-hua WANG,Ya-zhen LI,Jia-hui ZHAI,Bao-qi YAN,Lu-lu ZHANG,Xing-wang XIE,Zi-yu LI,Jia-fu JI. Preclinical study of T cell receptor specifically reactive with KRAS G12V mutation in the treatment of malignant tumors [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 884-895.
[7] Cai-peng QIN,Yu-xuan SONG,Meng-ting DING,Fei WANG,Jia-xing LIN,Wen-bo YANG,Yi-qing DU,Qing LI,Shi-jun LIU,Tao XU. Establishment of a mutation prediction model for evaluating the efficacy of immunotherapy in renal carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 663-668.
[8] Xi CHEN,Si-yue WANG,En-ci XUE,Xue-heng WANG,He-xiang PENG,Meng FAN,Meng-ying WANG,Yi-qun WU,Xue-ying QIN,Jing LI,Tao WU,Hong-ping ZHU,Jing LI,Zhi-bo ZHOU,Da-fang CHEN,Yong-hua HU. Exploring the association between de novo mutations and non-syndromic cleft lip with or without palate based on whole exome sequencing of case-parent trios [J]. Journal of Peking University (Health Sciences), 2022, 54(3): 387-393.
[9] FENG Ke,NI Jing-jing,XIA Yan-qing,QU Xiao-wei,ZHANG Hui-juan,WAN Feng,HONG Kai,ZHANG Cui-lian,GUO Hai-bin. Genetic analysis of three cases of acephalic spermatozoa syndrome caused by SUN5 mutation and the outcome of assisted reproductive technology [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 803-807.
[10] LIAO Xu-he,WANG Rong-fu,LIU Meng,CHEN Xue-qi,XIONG Yan,NONG Lin,YIN Lei,ZHANG Bing-ye,DU Yu-jing. Semiquantitative parameters of 18F-FDG PET/CT, gene mutation states of epidermal growth factor receptor and anaplastic lymphoma kinase in prognosis evaluation of patients with lung adenocarcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 246-254.
[11] WU Jun-yi,YU Miao,SUN Shi-chen,FAN Zhuang-zhuang,ZHENG Jing-lei,ZHANG Liu-tao,FENG Hai-lan,LIU Yang,HAN Dong. Detection of EDA gene mutation and phenotypic analysis in patients with hypohidrotic ectodermal dysplasia [J]. Journal of Peking University (Health Sciences), 2021, 53(1): 24-33.
[12] CAO Ze,WANG Le-tong,LIU Zhen-ming. Homologous modeling and binding ability analysis of Spike protein after point mutation of severe acute respiratory syndrome coronavirus 2 to receptor proteins and potential antiviral drugs [J]. Journal of Peking University (Health Sciences), 2021, 53(1): 150-158.
[13] Yi BAO,Juan-fen MO. Concordant point mutation of ETS-related gene (ERG) in tumor tissues from a synchronous multiple primary lung cancer: A case report [J]. Journal of Peking University (Health Sciences), 2020, 52(5): 971-974.
[14] Xue-jun LIANG,Li-ying GONG,Fei ZHOU,De-min ZHOU,Jing-jing ZHU. Pharmacological effects of site specific conjugated anti-human epidermal growth factor receptor 2-antibody drug conjugate using unnatural amino acid technology [J]. Journal of Peking University(Health Sciences), 2019, 51(5): 797-804.
[15] Zhu YOU,Li-li XU,Xue-fen LI,Jian-yun ZHANG,Jing DU,Li-sha SUN. BRAF gene mutations in ameloblastic fibromas [J]. Journal of Peking University(Health Sciences), 2019, 51(1): 4-5.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!